Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Can we safely target the WNT pathway?
FDA Approves First Drug for Lou Gehrig's Disease
Selective depression of low-release probability excitatory synapses by sodium channel blockers.
Picornavirus infection leading to immunosuppression.
Minocycline effects on the CSF proteome of Experimental Autoimmune Encephalomyelitis rats.
Submembranous cytoskeletons stabilize nodes of Ranvier.
The therapeutic value of yoga in neurological disorders.
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Indicators for cognitive performance and subjective cognitive complaints in multiple sclerosis: a role for advanced MRI?
Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress.
Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies.
Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis.
Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence.
Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned.
A Study of the Safety and Tolerability of MEDI-551 in Scleroderma
Unemployment in multiple sclerosis (MS): utility of the MS Functional Composite and cognitive testing.
Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide.
Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
A signal-to-noise-ratio-based analysis of multifocal visual-evoked potentials in multiple sclerosis risk assessment.
A Patient with Leiden V Mutation, Multiple Sclerosis, Psoriasis, and Sicca Syndrome: Could Celecoxib and Fingolimod Adversely Affect the Heart?
Purinergic trophic signalling in glial cells: functional effects and modulation of cell proliferation, differentiation, and death.
Peroxisome proliferator-activated receptor (PPAR)α and -γ regulate IFNγ and IL-17A production by human T cells in a sex-specific way.
Cost-sharing and initiation of disease-modifying therapy for multiple sclerosis.
Association of HLA-DRB1*1501 tagging rs3135388 gene polymorphism with multiple sclerosis.
Pages
« first
‹ previous
…
206
207
208
209
210
211
212
213
214
…
next ›
last »